These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
85 related articles for article (PubMed ID: 7161656)
1. Recombinant DNA as a paradigm of a new technology: its impact on regulation by the Food and Drug Administration. Miller HI J Parenter Sci Technol; 1982; 36(6):248-50. PubMed ID: 7161656 [No Abstract] [Full Text] [Related]
2. FDA, OSHA, and EPA regulation of the recombinant DNA technology. Korwek EL J Parenter Sci Technol; 1982; 36(6):251-5. PubMed ID: 7161657 [No Abstract] [Full Text] [Related]
3. The role of the Food and Drug Administration in the regulation of the products of recombinant DNA technology. Goldberg M; Miller HI Recomb DNA Tech Bull; 1981 Apr; 4(1):15-8. PubMed ID: 7255754 [TBL] [Abstract][Full Text] [Related]
4. The Food and Drug Administration's Points to Consider in Recombinant DNA Technology. Recomb DNA Tech Bull; 1984 Mar; 7(1):38-9. PubMed ID: 6587446 [No Abstract] [Full Text] [Related]
5. Biotechnology: can a new technology survive? Withers WW; Kenworthy PG St Louis Univ Law J; 1987; 31(3):673-97. PubMed ID: 11650845 [No Abstract] [Full Text] [Related]
6. Drug regulation. Gross M Nature; 1990 Jun; 345(6277):657. PubMed ID: 2359442 [No Abstract] [Full Text] [Related]
7. Supplement to the points to consider in the production and testing of new drugs and biologicals produced by recombinant DNA technology: nucleic acid characterization and genetic stability. Biologicals; 1993 Mar; 21(1):81-3. PubMed ID: 8217122 [No Abstract] [Full Text] [Related]
8. Recombinant DNA and the law: review of some general legal considerations. Korwek EL Gene; 1981 Oct; 15(1):1-5. PubMed ID: 7297854 [No Abstract] [Full Text] [Related]
10. FDA to fast-track recombinant drugs. Am Pharm; 1981 Feb; NS21(2):19. PubMed ID: 7211687 [No Abstract] [Full Text] [Related]
11. Engineering the therapies of tomorrow. Coghlan A New Sci; 1993 Apr; 138(1870):26-31. PubMed ID: 11656235 [No Abstract] [Full Text] [Related]
12. FDA industry relations, a fresh approach. Byers TE J Parenter Sci Technol; 1983; 37(3):105-6. PubMed ID: 6688270 [No Abstract] [Full Text] [Related]
13. Perspectives on the FDA status of drug products manufactured by the recombinant DNA technique. Korwek EL; Trinker DS Food Drug Cosmet Law J; 1981 Oct; 36(10):517-35. PubMed ID: 11650658 [No Abstract] [Full Text] [Related]
14. Regulation of genetic modification of organisms: science or emotion? Malinowski MJ J Biolaw Bus; 1998; 1(3):3-7. PubMed ID: 11657280 [No Abstract] [Full Text] [Related]
15. Obstacles and opportunities in new drug development. Kaitin KI Clin Pharmacol Ther; 2008 Feb; 83(2):210-2. PubMed ID: 18202685 [No Abstract] [Full Text] [Related]
16. Biomarker development, commercialization, and regulation: individualization of medicine lost in translation. Wilson C; Schulz S; Waldman SA Clin Pharmacol Ther; 2007 Feb; 81(2):153-5. PubMed ID: 17259939 [No Abstract] [Full Text] [Related]
17. Clear-cut biotechnology regulations are a must. Jefferson EG Med Mark Media; 1985 Jul; 20(7):28-9, 32-3. PubMed ID: 10272849 [No Abstract] [Full Text] [Related]
18. Influence that research and technological developments have had on the ability of the FDA to protect the public health. Novitch M Ann Ist Super Sanita; 1985; 21(4):459-61. PubMed ID: 3838000 [No Abstract] [Full Text] [Related]
19. Medical devices; general and plastic surgery devices; classification of absorbable poly(hydroxybutyrate) surgical suture produced by recombinant DNA technology. Final rule. Food and Drug Administration, HHS Fed Regist; 2007 Aug; 72(149):43144-6. PubMed ID: 17682290 [TBL] [Abstract][Full Text] [Related]
20. The new RAC: restructuring of the National Institutes of Health recombinant DNA Advisory Committee. Beach JE Food Drug Law J; 1999; 54(1):49-53. PubMed ID: 11758560 [No Abstract] [Full Text] [Related] [Next] [New Search]